The discovery of a novel series of 2-(4-pyridyl)thienopyridinone GSK-3β inhibitors is reported. X-ray crystallography reveals its binding mode and enables rationalization of the SAR. The initial optimization of the template for improved cellular activity and predicted CNS penetration is also presented.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bmcl.2011.06.050 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!